Liu et al. (2021) developed a highly innovative nanomedicine aimed at improving the therapeutic efficacy for breast cancer treatment.162 The approach involved copper-doped layered double hydroxide (Cu-LDH) nanoparticles, which were co-loaded with two FDA-approved anticancer agents—5-fluorouracil (5-FU) and albumin-bound paclitaxel (nAb-PTX). This evidence concerns the gene ALB and breast cancer.